PALO ALTO, Calif., Feb. 6 /PRNewswire/ -- Affymax, Inc., a clinical-stage pharmaceutical company, today announced that Arlene M. Morris, the Company’s president and chief executive officer will present at the 8th Annual BIO CEO & Investor Conference on Tuesday, February 14, at 10:30 a.m. EST at The Waldorf- Astoria Hotel in New York.
Ms. Morris will provide an update on the clinical development program for Hematide(TM), a novel peptide-based drug designed to stimulate the production of red blood cells and the Company’s first product candidate to enter the clinic. Hematide is being studied in Phase 2 clinical trials in the U.S. and Europe in patients with anemia associated with chronic kidney disease and cancer.
About Affymax
Affymax, Inc. is a clinical-stage pharmaceutical company that is developing a rich pipeline of synthetic peptide-based drugs against clinically validated targets for the treatment of kidney diseases and cancer. Hematide(TM), the Company’s first product candidate to enter the clinic, is a novel peptide-based drug designed to stimulate the production of red blood cells. It is in Phase 2 trials for the treatment of anemia associated with chronic kidney disease and cancer. For more information go to www.affymax.com.
Affymax, Inc.
CONTACT: Mary Fermi, Senior Director, Commercial Development of Affymax,Inc., +1-650-812-8722; or Daryl Messinger of WeissComm Partners, Inc/,+1-415-999-2361, or daryl@weisscommpartners.com, for Affymax, Inc.
Web site: http://www.affymax.com/
